Clinical Trials Logo

Melanoma clinical trials

View clinical trials related to Melanoma.

Filter by:

NCT ID: NCT04977453 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Start date: July 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101 as a single agent or in combination with pembrolizumab, lenvatinib or local radiotherapy (RT) over a range of advanced and/or metastatic solid tumors.

NCT ID: NCT04971499 Not yet recruiting - Melanoma Clinical Trials

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

Start date: October 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase 1/2 trial will be conducted in two parts. Part 1 (Dose Confirmation) is designed to confirm the safety and tolerability of the planned dose of dapansutrile (1000 mg BID) in combination with pembrolizumab. Part 1 will consist of up to 2 dose confirmation cohorts to evaluate the safety and tolerability of dapansutrile + pembrolizumab in patients with PD-1 resistant melanoma to confirm the safety of the recommended part 2 dose (RP2D). Part 1 will include a lead-in phase of dapansutrile monotherapy at 1000 mg PO BID. At day 15, combination therapy with pembrolizumab will be initiated. Part 2 (Dose Expansion) is designed to assess preliminary efficacy of dapansutrile + pembrolizumab in PD-1 resistant melanoma. Once all patients in Part 1 have completed 4 weeks of dapansutrile therapy, the expansion phase will start enrolling. Part 2 will also include a 14-day lead-in period of dapansutrile monotherapy at the RP2D.

NCT ID: NCT04969419 Active, not recruiting - Melanoma (Skin) Clinical Trials

Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo

Start date: June 18, 2021
Phase:
Study type: Observational

This study examines melanoma and nonmelanoma skin cancer in people diagnosed with vitiligo compared to matched controls.

NCT ID: NCT04967196 Not yet recruiting - Metastatic Melanoma Clinical Trials

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

Start date: July 30, 2021
Phase: Phase 1
Study type: Interventional

This phase I trial identifies the best dose of ipilimumab that can be administered through the DoseConnect device followed by nivolumab in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT04961619 Not yet recruiting - Melanoma Clinical Trials

Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.

LEAD Melanoma
Start date: October 20, 2021
Phase:
Study type: Observational

Non-interventional (observational) cohort prospective real life study with primary and secondary data collection from patients on adjuvant treatment with dabrafenib + trametinib in patients with completely resected high-risk stage III (stage IIIA [lymph node > 1mm], IIIB, IIIC and IIID according to AJCC 8th edition) melanoma in Turkey.

NCT ID: NCT04955743 Not yet recruiting - Melanoma Clinical Trials

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Start date: September 2021
Phase: Phase 2
Study type: Interventional

This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1 experienced patients with untreated brain metastases: 1) melanoma and 2) renal cell carcinoma (RCC).

NCT ID: NCT04955262 Withdrawn - Metastatic Melanoma Clinical Trials

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

Start date: August 2019
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to investigate the utility of the new investigational imaging agent ⁸⁹Zr Df-IAB22M2C (CD8 PET/CT tracer) to monitor CD8 T-cell expansion and trafficking within tumors and associated tissues in patients with metastatic melanoma undergoing treatment with bempegaldesleukin and nivolumab as a single agent and in combination.

NCT ID: NCT04951583 Not yet recruiting - Advanced Melanoma Clinical Trials

Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma

FMT-LUMINATE
Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

The aim of this study is to assess the anti-tumor activity of FMT administered in combination with ICI therapy.

NCT ID: NCT04949113 Not yet recruiting - Clinical trials for Malignant Melanoma Stage III

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

NADINA
Start date: July 2021
Phase: Phase 3
Study type: Interventional

This is an international (Australia, Europe, and USA) open-label two-arm randomized phase 3 trial including 420 stage III (≤3 resectable in-transit metastases allowed) cutaneous or unknown primary melanoma patients. Patients will be randomized 1:1 to receive either 2 cycles of neoadjuvant ipilimumab 80 mg + nivolumab 240 mg every 3 weeks followed by a total lymph node dissection (TLND) and, if applicable, resection of in-transit metastases (arm A) versus standard upfront TLND +/- resection of in-transit metastases followed by 12 cycles adjuvant nivolumab 480 mg every 4 weeks (arm B). Patients not achieving a pathologic response in arm A will also receive adjuvant nivolumab 480 mg every 4 weeks for 46 weeks (11 cycles). In case of BRAF V600E/K mutation-positivity, patients from arm A not achieving a pathologic response (>50% viable tumor) will be treated with adjuvant dabrafenib plus trametinib for 46 weeks. Patients will be treated in the study in both arms until melanoma progression to irresectable stage III or stage IV disease, disease recurrence, unacceptable toxicity, subject withdrawal of consent or until end of study treatment. An interim analysis will be performed after 60 events have occurred. The data safety monitory board (DSMB) will be ad hoc consulted when unexpected toxicities are reported. Patients will be followed by 12 weekly CT scans until end of year 3 and then until year 5 according to the institute's standards.

NCT ID: NCT04941430 Not yet recruiting - Metastatic Melanoma Clinical Trials

7T MRI Scan for the Early Detection of Melanoma Brain Metastases

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

This clinical trial studies the use of 7-Tesla (7T) magnetic resonance imaging (MRI) in detecting melanoma that has spread to the brain (melanoma brain metastases). The standard MRI brain imaging is done on 3T or similar MRI machine, but the 7T MRI machine has a larger magnet which has been shown to have superior resolution of the brain and of non-cancerous brain lesions. Diagnostic procedures such as 7T MRI may help find and diagnose melanoma brain metastases earlier than standard 3T MRI.